Agree with your observation... and, I think hottod made an early...

Agree with your observation... and, I think hottod made an early stab at the "A" as being representative of "Allogeneic". There's enough on our website to suggest that it could be Allogeneic too.



With the two arms of the Cell Pryme platform being synergistic and totally compatible with OmniCAR, its likely that the Cell Pryme-A may have even bigger than Cell Pryme-M given its longer term significance and reach. But, yeah, Threebeez, Cell Pryme-A is likely to have less immediate application in terms monetisation... but who knows... maybe there has been enough R&D in the industry to see this happen sooner for PTX than we think. Plenty of milestones being hit by our guys and in the field by others. Exciting times ahead for sure. the industry attempts to drive down the cost and time of delivering CAR-T therapy to patients, OmniCAR’s flexibility and control will be an increasingly valuable tool, by removing the need for multiple manufacturing runs per patient, and its compatibility with allogeneic (“off the shelf”) T-cells. OmniCAR is potentially compatible with many other CAR approaches including NK cells; macrophages and stem cells.